Literature DB >> 25957964

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.

Chad E Mire1, Joan B Geisbert1, Krista M Versteeg1, Natalia Mamaeva2, Krystle N Agans1, Thomas W Geisbert1, John H Connor2.   

Abstract

The filoviruses, Marburg marburgvirus (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SEBOV), cause severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which encode a filovirus glycoprotein (GP) in place of the VSV glycoprotein, have shown 100% efficacy against homologous filovirus challenge in rodent and NHP studies. Here, we examined the utility of a single-vector, single-injection trivalent rVSV vector expressing MARV, ZEBOV, and SEBOV GPs to protect against MARV-, ZEBOV-, and SEBOV-induced disease in outbred Hartley guinea pigs where we observed protection from effects of all 3 filoviruses.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Ebola virus; Marburg virus; cross-protection; filovirus; guinea pig; trivalent; vaccine; vesicular stomatitis virus

Mesh：

Substances：

Year:  2015        PMID： 25957964      PMCID： PMC4564539          DOI： 10.1093/infdis/jiv126

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

1.  The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancois; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

2.  The protease-sensitive loop of the vesicular stomatitis virus matrix protein is involved in virus assembly and protein translation.

Authors:  Chad E Mire; Michael A Whitt
Journal:  Virology       Date:  2011-05-18       Impact factor: 3.616

3.  Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig.

Authors:  Robert W Cross; Karla A Fenton; Joan B Geisbert; Chad E Mire; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2015-06-02       Impact factor: 5.226

4.  Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Authors:  Andrea Marzi; Hideki Ebihara; Julie Callison; Allison Groseth; Kinola J Williams; Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Emergence of Zaire Ebola virus disease in Guinea.

Authors:  Sylvain Baize; Delphine Pannetier; Lisa Oestereich; Toni Rieger; Lamine Koivogui; N'Faly Magassouba; Barrè Soropogui; Mamadou Saliou Sow; Sakoba Keïta; Hilde De Clerck; Amanda Tiffany; Gemma Dominguez; Mathieu Loua; Alexis Traoré; Moussa Kolié; Emmanuel Roland Malano; Emmanuel Heleze; Anne Bocquin; Stephane Mély; Hervé Raoul; Valérie Caro; Dániel Cadar; Martin Gabriel; Meike Pahlmann; Dennis Tappe; Jonas Schmidt-Chanasit; Benido Impouma; Abdoul Karim Diallo; Pierre Formenty; Michel Van Herp; Stephan Günther
Journal:  N Engl J Med       Date:  2014-04-16       Impact factor: 91.245

6.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Authors:  M Bray; K Davis; T Geisbert; C Schmaljohn; J Huggins
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

7.  Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors:  B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

8.  Development and characterization of a mouse model for Marburg hemorrhagic fever.

Authors:  Kelly L Warfield; Steven B Bradfute; Jay Wells; Loreen Lofts; Meagan T Cooper; D Anthony Alves; Daniel K Reed; Sean A VanTongeren; Christine A Mech; Sina Bavari
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

9.  Evaluation in nonhuman primates of vaccines against Ebola virus.

Authors:  Thomas W Geisbert; Peter Pushko; Kevin Anderson; Jonathan Smith; Kelly J Davis; Peter B Jahrling
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

10.  Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA.

Authors:  Raul Ursic-Bedoya; Chad E Mire; Marjorie Robbins; Joan B Geisbert; Adam Judge; Ian MacLachlan; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2013-08-29       Impact factor: 5.226
View more
  16 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

2.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 3.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Authors:  Chad E Mire; Joan B Geisbert; Viktoriya Borisevich; Karla A Fenton; Krystle N Agans; Andrew I Flyak; Daniel J Deer; Herta Steinkellner; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Andrew Hiatt; Do H Kim; Michael H Pauly; Jesus Velasco; Kevin J Whaley; James E Crowe; Larry Zeitlin; Thomas W Geisbert
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

5.  Pre-clinical development of a vaccine against Lassa fever.

Authors:  L Banadyga; D R Stein; X Qiu; D Safronetz
Journal:  Can Commun Dis Rep       Date:  2018-06-07

6.  Development and Characterization of a Guinea Pig-Adapted Sudan Virus.

Authors:  Gary Wong; Shihua He; Haiyan Wei; Andrea Kroeker; Jonathan Audet; Anders Leung; Todd Cutts; Jill Graham; Darwyn Kobasa; Carissa Embury-Hyatt; Gary P Kobinger; Xiangguo Qiu
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

7.  The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.

Authors:  Robert W Cross; Chad E Mire; Viktoriya Borisevich; Joan B Geisbert; Karla A Fenton; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2016-05-24       Impact factor: 5.226

Review 8.  Novel viral vectors in infectious diseases.

Authors:  Ian R Humphreys; Sarah Sebastian
Journal:  Immunology       Date:  2017-09-26       Impact factor: 7.397

9.  Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice.

Authors:  Weiwei Gai; Xuexing Zheng; Chong Wang; Hualei Wang; Yongkun Zhao; Qi Wang; Gary Wong; Weijiao Zhang; Na Feng; Boning Qiu; Hang Chi; Nan Li; Tiecheng Wang; Yuwei Gao; Junjie Shan; Songtao Yang; Xianzhu Xia
Journal:  Virol J       Date:  2017-10-25       Impact factor: 4.099

Review 10.  The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.

Authors:  Ellen Suder; Wakako Furuyama; Heinz Feldmann; Andrea Marzi; Emmie de Wit
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.